Home Page Potential Lawsuit Prevacid Side Effects
Prevacid Side Effects
Prevacid is a proton pump inhibitor, used to treat symptoms of acid reflux. According to reports, Prevacid side effects could include an increased risk acute kidney injury and chronic kidney disease. Studies suggest that the risk of Prevacid complications and the risk of proton pump inhibitor side effects increases as the length of use or the medication dosage increases. Prevacid lawsuits allege patients have suffered serious side effects as a result of using the medication.
Proton Pump Inhibitors (PPIs) such as Prevacid (lansoprazole) are used to treat gastroesophageal reflux disease, heartburn, stomach and small intestine ulcers, and esophageal inflammation. They work by blocking the enzyme in the stomach that promotes the production of acid, thereby decreasing the patient's stomach acid.
Several studies have suggested the use of Prevacid or other proton pump inhibitors could be linked to serious side effects.
Prevacid Side Effects
A study published April 2016 in the Journal of the American Society of Nephrology found that patients who took proton pump inhibitors for more than 30 days had an increased risk of renal outcomes—including kidney failure or chronic kidney disease—compared with those who took a PPI for 30 days or less. Researchers called the association "graded" indicating that patients who took the medications longer were at higher risk of renal outcomes.
In February 2016 a study published in JAMA Internal Medicine found that use of proton pump inhibitors was associated with a higher risk of chronic kidney disease.
A study published in 2015 in the journal CMAJ Open (4/16/15) suggested that senior citizens who started proton pump inhibitor therapy were at an increased risk of acute kidney injury and acute interstitial nephritis.
In 2014, the FDA required new warning information regarding a form of Prevacid kidney problems, called acute interstitial nephritis, which involves sudden inflammation of the kidneys. Acute interstitial nephritis can lead to more severe problems. The new Prevacid warning information states: "Acute interstitial nephritis has been observed in patients taking PPIs including Prevacid. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to idiopathic hypersensitivity reaction. Discontinue Prevacid if acute intestinal nephritis develops." In 2012, the US Food and Drug Administration (FDA) issued a warning that use of proton pump inhibitors could be associated with an increased risk of Clostridium difficile-associated diarrhea.
Prevacid FDA Warnings
In 2010, the FDA revised the labels of proton pump inhibitors to warn about the possible increased risk of fractures in the hip, wrist, and spine associated with the medications.
A lawsuit has been filed in New York by Terry Buzbee, who alleges that the makers of Nexium and Prevacid failed to warn patients about the potential risk of kidney disease linked to the use of the proton pump inhibitors. According to the lawsuit, Buzbee began taking Nexium and Prevacid in 2006. The lawsuit alleges he suffered acute kidney injury that resulted in his need for life-long medical care and monitoring.
PrevacidLegal HelpIf you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on
PREVACID LEGAL ARTICLES AND INTERVIEWS
Do Medication Guides for PPI Kidney Disease and Prevacid Lack Consistency?
Washington, DC: It would come as no surprise that a common scourge amongst Americans remains acid reflux, and similar maladies. For them, a common prescription for a Proton Pump Inhibitor (PPI) serves to provide relief, and minimize the effects of heartburn and related ailments such as gastroesophageal reflux disease (GERD) [READ MORE]
READ MORE [ Proton Pump Inhibitor Settlements and Legal News ]
READ MORE [ Drugs/Medical Settlements and Legal News ]
READ MORE [ Personal Injury Settlements and Legal News ]
ADD YOUR COMMENT ON THIS ISSUE